CA-LDA-CAPITAL
24.6.2021 07:02:13 CEST | Business Wire | Press release
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months, including those aimed at combating COVID-19.
Both Pharmsynthez and LDA view this capital allocation not only as an investment into the Company but also as a starting point for a long-term strategic partnership to advance Pharmsynthez’s promising projects in the field of innovative pharmaceutical technologies and development of the latest treatments for complex diseases.
LDA Capital’s investments will accelerate Pharmsynthez PJSC projects in all aspects. The Company’s business plan until 2025 allows for the introduction of several highly profitable original drugs (Epolong® and other finished dosage forms) to the domestic market, an increase in the production of active pharmaceutical ingredients, and the launch of the new drugs, such as vaccines that solve various purposes, including: treatment of multiple sclerosis (Xemys®), prevention of hepatitis B (Sci-B-Vac®), COVID-19 and a number of other diseases. In addition, the Company is preparing to bring to market and then localize the production of several generic drugs for the treatment of orphan and oncological diseases, as well as to launch the production of monoclonal antibodies drugs and dry cell culture media for the pharmaceutical industry, becoming a leader in the EAEU market.
Efim Prilezhaev, General Director of Pharmsynthez PJSC, commented: “We are pleased that our partnership with LDA Capital as one of the most successful progressive investors in an environment where interest in pharmaceutical technologies is at an all-time high. Nowadays, the growing demand for innovative developments in the field of biotechnology, the growing risks of pandemics and infectious diseases provide significant growth opportunities for players in this difficult market. We are confident that our partnership with LDA will help deliver outstanding results for the benefit of society.”
Warren Baker, the Managing Partner of LDA Capital, stated: “On the back of secular growth trends in cell culture-based vaccines and monoclonal antibodies (mAb), LDA is enthused to partner with one of the leading Russian pharmaceutical manufacturers. We are excited by Pharmsynthez’s scientific potential and look forward to our continuous cooperation as we remain steadfast on our commitment to providing alternative capital solutions to innovative companies in the global healthcare sector.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005990/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Awarded Multiple Offshore Drilling Contracts by Mubadala Energy for Tangkulo Deepwater Development in Indonesia12.2.2026 14:00:00 CET | Press release
Contracts support offshore gas development with first gas targeted before end of 2028 Global energy technology company SLB (NYSE: SLB) has been awarded multiple offshore drilling services contracts by Mubadala Energy, the Abu Dhabi headquartered international energy company, for the Tangkulo natural gas deepwater development and associated exploration and appraisal drilling activities in the Andaman Sea, offshore Indonesia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212809124/en/ The project will leverage SLB’s offshore and deepwater technologies, including real-time downhole monitoring, to reduce operational risk, improve well placement and strengthen project economics. Under the awards, SLB will work with Mubadala Energy to deliver integrated drilling and well services across the full well life cycle. The scope includes directional drilling, drilling fluids, cementing, wireline, slickline, coiled tubing, well testin
Align Partners Issues Formal Shareholder Proposals to Dentium12.2.2026 13:43:00 CET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Dentium Co., Ltd. (“Dentium” or the “Company”), has submitted formal shareholder proposals for inclusion in the agenda of Dentium’s upcoming 26th Annual General Meeting (“AGM”), urging the Company to strengthen governance practices and improve capital allocation discipline. Align Partners noted that, given shareholder proposals will be presented at this year’s AGM, Dentium should follow the Korea Exchange (KRX) Corporate Governance Key Indicators by publishing the AGM convocation notice at least four weeks prior to the meeting date and adopting an electronic voting system to enhance shareholder participation. Dentium is widely recognized as a global leader in the dental implant industry, supported by superior technology and more than 23 years of long-term clinical data. Despite this strong positioning, Align Partners believes the Company continues to trade at a meaningful discount. As of February 11, 2026, Dent
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to SoluM12.2.2026 13:42:00 CET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of SoluM Co., Ltd. (“SoluM” or the “Company”), has submitted formal shareholder proposals for inclusion in the agenda of SoluM’s 2026 Annual General Meeting (“AGM”) and issued its first public shareholder letter to the Company’s Board of Directors. Align Partners requested that SoluM’s Board and management provide a public written response to the shareholder letter by the AGM convocation notice deadline ahead of the March 2026 meeting. The campaign reflects Align Partners’ view that meaningful governance reforms and strategic focus are urgently needed to unlock shareholder value. SoluM operates a high-growth Electronic Shelf Label (“ESL”) business with strong global positioning and attractive long-term market potential. Despite this, the Company’s share price has remained near historical lows since its listing. As of February 11, 2026, SoluM trades at a last-twelve-month EV/EBIT multiple of 28.9x, representing a s
GigaDevice Extends European Reach with SEMITRON Partnership for DACH region12.2.2026 10:52:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has entered into a distribution agreement with SEMITRON, a leading electronic component distributor that specializes with a focus on the DACH region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203746978/en/ Under the terms of the deal, SEMITRON is set to supply both GigaDevice's leading Flash, MCU, power and sensor lines in conjunction with field application engineering support to customers in the industrial, automotive and communication technology sectors. In particular, SEMITRON offers professional test house services, technical know-how and local on-the-ground expertise and support. The partnership further extends GigaDevice's reach into this major European market, with on the ground support in Germany, Austria, Switzerland. Jürgen Rohland, Managing Director of SEMITRON W. Röck Gmb
Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing12.2.2026 10:48:00 CET | Press release
Mass production commences for HBM4 with consistent transfer speed of 11.7Gbps, capable of up to 13GbpsLeading-edge DRAM with 4nm logic base die maximizes performance, reliability and energy efficiency for next-generation datacentersSecure process technology and supply capabilities strengthen Samsung’s HBM roadmap beyond HBM4 Samsung Electronics Co., Ltd., a global leader in advanced memory technology, today announced that it has begun mass production of its industry-leading HBM4 and has shipped commercial products to customers. This achievement marks a first in the industry, securing an early leadership position in the HBM4 market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212674509/en/ Samsung Ships Industry-First Commercial HBM4 With Ultimate Performance for AI Computing By proactively leveraging its most advanced 6th-generation 10 nanometer (nm)-class DRAM process (1c), the company achieved stable yields and indus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom